U.S. FDA Seizes Chinese Heparin From Medical Devices Firm
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA ordered 11 lots of contaminated heparin removed from Celsus Laboratories, which obtained the drug product from China to include in medical devices. The agency ordered the seizures on grounds the products contained over-sulfated chondroitin sulfate. FDA advised companies that may have obtained heparin from Cincinnati-based Celsus to determine if the drug they received came from one of the 11 batches. The agency said it has contacted other countries to warn them of the newly found contaminated heparin produced in China. (Click here for more - a subscription may be required
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.